By Rebecca J. Kaufman

The promise of stem cell technology has generated more than a few headlines. So too have the politics of stem cells, namely human embryonic stem cells (hESC). As recently as last week, President Bush vetoed a bill that would have authorized expanded federal support for hESC research, citing moral issues. In the absence of new legislation, federal funding is limited to research on hESC lines derived before August 9, 2001; which many researchers have argued are inadequate. (more…)

by Stephanie Adams
Executive Director, Southeast BIO

Large and impressive displays by Southeastern states at last week’s BIO International Convention in Boston are evidence of the importance of the biotech industry to the economic growth of the individual states and the region as a whole. (more…)

By RICK SMITH

Posted: Mar. 12, 2007

RESEARCH TRIANGLE PARK, N.C. – Stephanie Adams, a patent agent with the King & Spalding law firm in Atlanta since 2002, is the new executive director of the Southeast BIO. (more…)

By Rebecca Kaufman, Counsel, King & Spalding LLP, and Chair, Southeast BIO

In 2005, the $540 million purchase of Emory University’s royalty interest in emtricitabine (Emtriva) was big news. The largest ever deal of its kind for a U.S. university, it brought significant recognition and resources to Emory’s research programs. (more…)

ATLANTA, GA – Atlanta-based Transfusion & Transportation Technologies, Inc., an early-stage spin-out from Emory University that develops specialized automated multi-analyzers and other instrumentation for use in blood centers, was the last company standing at the end of the 2006 Southeastern BIO Investor Forum’s Early-Stage Shootout. (more…)